JP2019524883A5 - - Google Patents

Download PDF

Info

Publication number
JP2019524883A5
JP2019524883A5 JP2019529309A JP2019529309A JP2019524883A5 JP 2019524883 A5 JP2019524883 A5 JP 2019524883A5 JP 2019529309 A JP2019529309 A JP 2019529309A JP 2019529309 A JP2019529309 A JP 2019529309A JP 2019524883 A5 JP2019524883 A5 JP 2019524883A5
Authority
JP
Japan
Prior art keywords
alkyl
cyclyl
heterocyclyl
group
membered
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2019529309A
Other languages
English (en)
Japanese (ja)
Other versions
JP6959663B2 (ja
JP2019524883A (ja
Filing date
Publication date
Priority claimed from CN201610647295.0A external-priority patent/CN107698593A/zh
Application filed filed Critical
Publication of JP2019524883A publication Critical patent/JP2019524883A/ja
Publication of JP2019524883A5 publication Critical patent/JP2019524883A5/ja
Application granted granted Critical
Publication of JP6959663B2 publication Critical patent/JP6959663B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2019529309A 2016-08-09 2017-07-27 Fgfr阻害剤としての複素環化合物 Expired - Fee Related JP6959663B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CN201610647295.0A CN107698593A (zh) 2016-08-09 2016-08-09 作为fgfr抑制剂的杂环化合物
CN201610647295.0 2016-08-09
PCT/CN2017/094620 WO2018028438A1 (zh) 2016-08-09 2017-07-27 作为fgfr抑制剂的杂环化合物

Publications (3)

Publication Number Publication Date
JP2019524883A JP2019524883A (ja) 2019-09-05
JP2019524883A5 true JP2019524883A5 (cg-RX-API-DMAC10.html) 2020-07-16
JP6959663B2 JP6959663B2 (ja) 2021-11-02

Family

ID=61162708

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2019529309A Expired - Fee Related JP6959663B2 (ja) 2016-08-09 2017-07-27 Fgfr阻害剤としての複素環化合物

Country Status (7)

Country Link
US (1) US10752631B2 (cg-RX-API-DMAC10.html)
EP (1) EP3498706A4 (cg-RX-API-DMAC10.html)
JP (1) JP6959663B2 (cg-RX-API-DMAC10.html)
KR (1) KR20190035870A (cg-RX-API-DMAC10.html)
CN (2) CN107698593A (cg-RX-API-DMAC10.html)
CA (1) CA3032921A1 (cg-RX-API-DMAC10.html)
WO (1) WO2018028438A1 (cg-RX-API-DMAC10.html)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20200003390A (ko) 2017-05-08 2020-01-09 그릿스톤 온콜로지, 인코포레이티드 알파바이러스 신생항원 벡터
CN114364798A (zh) 2019-03-21 2022-04-15 欧恩科斯欧公司 用于治疗癌症的Dbait分子与激酶抑制剂的组合
AU2020278566A1 (en) * 2019-05-17 2021-12-23 Kinnate Biopharma Inc. Inhibitors of fibroblast growth factor receptor kinases
WO2020243719A1 (en) 2019-05-30 2020-12-03 Gritstone Oncology, Inc. Modified adenoviruses
JP2023500906A (ja) 2019-11-08 2023-01-11 インサーム(インスティテュ ナシオナル ドゥ ラ サンテ エ ドゥ ラ ルシェルシェ メディカル) キナーゼ阻害剤に対する獲得抵抗性を有するがんの処置方法
WO2021148581A1 (en) 2020-01-22 2021-07-29 Onxeo Novel dbait molecule and its use
CA3181162A1 (en) 2020-06-05 2021-12-09 Stephen W. Kaldor Inhibitors of fibroblast growth factor receptor kinases
CA3181209A1 (en) * 2020-06-05 2021-12-09 Stephen W. Kaldor Inhibitors of fibroblast growth factor receptor kinases
CN116438308A (zh) 2020-08-06 2023-07-14 磨石生物公司 多表位疫苗盒
CN112480109B (zh) * 2020-11-16 2022-04-01 浙江大学 吡啶并[2,3-b]吡嗪-3(4H)-酮类衍生物及其用途
EP4277903A4 (en) * 2021-01-12 2024-11-27 Beijing InnoCare Pharma Tech Co., Ltd. PROCESS FOR PREPARING (S)-1-(1-ACRYLOYLPYRROLIDIN-3-YL)-3-((3,5-DIMETHOXYPHENYL)ETHINYL)-5-(METHYLAMINO)-1H-PYRAZOL-4-CARBOXAMIDE
CN114853739B (zh) * 2021-02-03 2023-09-22 药雅科技(上海)有限公司 一种炔代吡嗪类fgfr抑制剂及其制备方法和用途
CN115043832B (zh) * 2021-03-08 2023-08-22 药雅科技(上海)有限公司 一种fgfr抑制剂炔代杂环类化合物及其制备方法和用途
CN120051471A (zh) * 2022-10-18 2025-05-27 首药控股(北京)股份有限公司 一种新型杂环化合物
CR20250458A (es) 2023-03-30 2025-11-21 Revolution Medicines Inc Composiciones para inducir la hidrólisis de ras gtp y sus usos
AU2024265078A1 (en) 2023-05-04 2025-12-11 Revolution Medicines, Inc. Combination therapy for a ras related disease or disorder
US20250049810A1 (en) 2023-08-07 2025-02-13 Revolution Medicines, Inc. Methods of treating a ras protein-related disease or disorder
US20250154171A1 (en) 2023-10-12 2025-05-15 Revolution Medicines, Inc. Ras inhibitors
WO2025171296A1 (en) 2024-02-09 2025-08-14 Revolution Medicines, Inc. Ras inhibitors
WO2025240847A1 (en) 2024-05-17 2025-11-20 Revolution Medicines, Inc. Ras inhibitors
WO2025255438A1 (en) 2024-06-07 2025-12-11 Revolution Medicines, Inc. Methods of treating a ras protein-related disease or disorder
WO2025265060A1 (en) 2024-06-21 2025-12-26 Revolution Medicines, Inc. Therapeutic compositions and methods for managing treatment-related effects
WO2026006747A1 (en) 2024-06-28 2026-01-02 Revolution Medicines, Inc. Ras inhibitors
WO2026015790A1 (en) 2024-07-12 2026-01-15 Revolution Medicines, Inc. Methods of treating a ras related disease or disorder
WO2026015801A1 (en) 2024-07-12 2026-01-15 Revolution Medicines, Inc. Methods of treating a ras related disease or disorder
WO2026015825A1 (en) 2024-07-12 2026-01-15 Revolution Medicines, Inc. Use of ras inhibitor for treating pancreatic cancer
WO2026015796A1 (en) 2024-07-12 2026-01-15 Revolution Medicines, Inc. Methods of treating a ras related disease or disorder

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1981890A2 (en) * 2006-01-25 2008-10-22 OSI Pharmaceuticals, Inc. UNSATURATED mTOR INHIBITORS
EP2657233B1 (en) 2012-01-19 2014-08-27 Taiho Pharmaceutical Co., Ltd. 3,5-disubstituted alkynylbenzene compound and salt thereof
MX2015011456A (es) * 2013-03-13 2016-05-31 Boston Biomedical Inc Derivados de 3-(arilo o heteroailo) metilenindolino-2-ona como inhibidores de cinasas de la via de las celulas madres cancerosas para el tratamiento del cancer.
JP6084292B2 (ja) 2013-07-18 2017-02-22 大鵬薬品工業株式会社 Fgfr阻害剤耐性癌の治療薬
KR101974254B1 (ko) * 2013-07-18 2019-04-30 다이호야쿠힌고교 가부시키가이샤 Fgfr 저해제의 간헐 투여용 항종양제
CN104341425B (zh) * 2013-08-08 2018-11-02 上海医药集团股份有限公司 氘代乙炔衍生物、其药物组合物及应用
SI3052476T1 (sl) * 2013-09-30 2020-12-31 Guangzhou Innocare Pharma Tech Co., Ltd. Substituirani nikotinimidni inhibitorji BTK in njihova priprava in uporaba pri zdravljenju raka, vnetja in avtoimunske bolezni
EP3184521B1 (en) * 2014-08-19 2021-10-06 Shanghai Haihe Pharmaceutical Co., Ltd. Indazole compounds as fgfr kinase inhibitors, preparation and use thereof

Similar Documents

Publication Publication Date Title
JP2019524883A5 (cg-RX-API-DMAC10.html)
JP2014193925A5 (cg-RX-API-DMAC10.html)
JP2015532295A5 (cg-RX-API-DMAC10.html)
JP2016540742A5 (cg-RX-API-DMAC10.html)
JP2015508103A5 (cg-RX-API-DMAC10.html)
JP2016530259A5 (cg-RX-API-DMAC10.html)
JP2015520140A5 (cg-RX-API-DMAC10.html)
JP2016510323A5 (cg-RX-API-DMAC10.html)
JP2016515561A5 (cg-RX-API-DMAC10.html)
JP2015505296A5 (cg-RX-API-DMAC10.html)
JP2017071634A5 (cg-RX-API-DMAC10.html)
JP2016505512A5 (cg-RX-API-DMAC10.html)
JP2014521688A5 (cg-RX-API-DMAC10.html)
JP2016512531A5 (cg-RX-API-DMAC10.html)
MA38323B1 (fr) Dérivés pyrimidone et leur utilisation dans le traitement, l'amélioration ou la prévention d'une maladie virale
JP2019522055A5 (cg-RX-API-DMAC10.html)
JP2016501221A5 (cg-RX-API-DMAC10.html)
JP2017531619A5 (cg-RX-API-DMAC10.html)
JP2016503797A5 (cg-RX-API-DMAC10.html)
JP2020097577A5 (cg-RX-API-DMAC10.html)
JP2016534063A5 (cg-RX-API-DMAC10.html)
JP2016510326A5 (cg-RX-API-DMAC10.html)
JP2016531126A5 (cg-RX-API-DMAC10.html)
JP2019535723A5 (cg-RX-API-DMAC10.html)
JP2014501766A5 (cg-RX-API-DMAC10.html)